Martin Akerman

Co-Founder and Chief Technology Officer
​​Envisagenics

​​​​

CTO and Co-Founder of Envisagenics
Dr. Martin Akerman is the CTO and Co-founder of Envisagenics. He is the inventor of SpliceCore®,
Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and
discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr.
Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®,
the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received
his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA
splicing can boost functionality of the human genome and trigger diseases.

Speech title & Synopsis

Unlocking the Potential of AI for High-Throughput Immunotherapy Drug Discovery Through RNA Splicing

• Envisagenics presents SpliceCore, an AI-powered target discovery platform with a focus on the identification of
novel, highly tumor-specific, and safe epitopes for immunotherapeutic development.
• Explore the cutting-edge technology behind SpliceCore and delve into its scientific foundation of alternative
splicing, a molecular process that simultaneously drives tumor progression while generating novel epitopes within
cancer cells — offering a promising foundation for novel therapies.
• Through compelling case studies and rigorous experimental validations, we showcase the predictive capabilities
of the SpliceCore platform and its ability to find novel tumor-specific epitopes.